---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report. Covers Cost-effectiveness evidence. 37 evidence topics quoted from 29 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics/cost-effectiveness"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report

<a id="economic-information-and-modeling-report"></a>

## 4 Economic Information and Modeling Report

<a id="heading-4.1"></a>

### 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

#### Summary: adrabetadex price and comparator prices

- Adrabetadex: no list price for Lembaz had been announced at approval; trade press reporting states that “List pricing for the new product has not yet been announced”. No budget impact model or cost-effectiveness analysis of adrabetadex has been published.
- ICER launch price report: the ICER Launch Price and Access Report (2026) gives an annual list price of $967,432.50 and a best annual net price estimate of $940,586.25 for Miplyffa (arimoclomol), using the dosing regimen for patients weighing 30 kg to 55 kg, and an annual list price of $701,321.42 and a best annual net price estimate of $576,661.54 for Aqneursa (levacetylleucine), using the dosing regimen for patients weighing 35 kg or more. ICER converted unit WAC prices to annual WAC prices using the dosage information on the FDA label, and had not previously reviewed the clinical effectiveness and cost-effectiveness of either drug.
- Arimoclomol: the wholesale acquisition cost of Miplyffa at its introduction on September 23, 2024 was $40,185 (47 mg), $53,010 (62 mg), $79,515 (93 mg), and $106,020 (124 mg), and the same values were reported to Texas for 1 January 2026. Federal Supply Schedule prices effective 01/01/2026 for a package of 90 range from $30,080.19 (47 mg) to $79,360.50 (124 mg).
- Levacetylleucine: the wholesale acquisition cost of an Aqneursa 1 gram sachet carton of 28 was $13,450 at its introduction on September 24, 2024 and on 1 January 2025, and the wholesale acquisition cost reported for Aqneursa on 1 January 2026 was $14,526. The Federal Supply Schedule price for a package of 28 is $13,339.54 and the Big Four price is $10,206.02. An Oklahoma Medicaid review gives $480.36 per packet, $57,643.20 per 30 days, and $691,718.40 per year at the FDA approved maximum dose of 4 g per day, based on NADAC, WAC, or SMAC and excluding rebates.
- Miglustat: Zavesca 100 mg has a Federal Supply Schedule price of $16,811.69 and a Big Four price of $12,589.91 for a package of 90, and a generic miglustat 100 mg product has a Federal Supply Schedule price of $4,644.83.
- Utilization and revenue: Zevra reported $34.0 million in Miplyffa revenue for the third quarter of 2026, 197 Miplyffa prescription enrollment forms since launch, and 134 participants enrolled in its global EAP as of September 30, 2026. Analysts at Delveinsight expect Aqneursa to generate $500 million in peak U.S. sales in NPC.

Source: [Pharmaphorum LEMBAZ approval report (2026)](https://pharmaphorum.com/news/berens-niemann-pick-drug-lembaz-cleared-fda); [ICER Launch Price and Access Report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_2026_Launch-Price-and-Access-Final-Report_ForPublication-1.pdf); [California Department of Health Care Access and Information Prescription Drugs Introduced to Market, MIPLYFFA (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22Date%20Introduced%20to%20Market%22%2C%22WAC%20at%20Introduction%22%2C%22Estimated%20Number%20of%20Patients%22%20FROM%20%220e3afcfc-a5eb-41c6-a633-deaa2bfb5710%22%20WHERE%20%22Drug%20Product%20Description%22%20LIKE%20%27Miplyffa%25%27); [Texas Department of State Health Services 2026 Annual WAC Report (2026)](https://www.dshs.texas.gov/sites/default/files/CP-TexasRX/files/2026-annual-wac-report_1026.xlsx); [Texas Department of State Health Services 2025 Annual WAC Report (2026)](https://www.dshs.texas.gov/sites/default/files/CP-TexasRX/files/2025-annual-wac-report_0226.xlsx); [Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026)](https://www.va.gov/opal/docs/nac/fss/vaFssPharmPrices.xlsx); [California Department of Health Care Access and Information Prescription Drugs Introduced to Market (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22Date%20Introduced%20to%20Market%22%2C%22WAC%20at%20Introduction%22%2C%22Estimated%20Number%20of%20Patients%22%2C%22Breakthrough%20Therapy%20Indicator%22%2C%22Priority%20Review%20Indicator%22%2C%22General%20Comments%22%20FROM%20%220e3afcfc-a5eb-41c6-a633-deaa2bfb5710%22%20WHERE%20%22NDC%20Number%22%20%3D%20%2783853010101%27); [Oklahoma Health Care Authority Drug Utilization Review Board packet (2025)](https://oklahoma.gov/content/dam/ok/en/okhca/docs/about/boards-and-committees/dur/2025/march/03122025%20DUR%20Packet.pdf); [Medicaid.gov State Drug Utilization Data 2026 (2026)](https://data.medicaid.gov/api/1/datastore/query/2957a7f9-9a15-453e-9afd-3bbdcbac8fd3/0?conditions%5B0%5D%5Bproperty%5D=ndc&conditions%5B0%5D%5Bvalue%5D=83853010101&conditions%5B0%5D%5Boperator%5D=%3D&conditions%5B1%5D%5Bproperty%5D=state&conditions%5B1%5D%5Bvalue%5D=XX&conditions%5B1%5D%5Boperator%5D=%3D&limit=20&properties%5B%5D=utilization_type&properties%5B%5D=state&properties%5B%5D=ndc&properties%5B%5D=year&properties%5B%5D=quarter&properties%5B%5D=suppression_used&properties%5B%5D=product_name&properties%5B%5D=units_reimbursed&properties%5B%5D=number_of_prescriptions&properties%5B%5D=total_amount_reimbursed&properties%5B%5D=medicaid_amount_reimbursed&properties%5B%5D=non_medicaid_amount_reimbursed&sorts%5B0%5D%5Bproperty%5D=quarter&sorts%5B0%5D%5Border%5D=asc&schema=false&keys=true&count=false); [Zevra Therapeutics third quarter 2026 results release (2026)](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000085/zvra-20261103xex991earnings.htm); [Fierce Pharma phase 3 results report (2026)](https://www.fiercepharma.com/pharma/intrabios-aqneursa-roll-eu-approval-races-toward-another-rare-disease-indication-phase-3-win)

<a id="topic-4.1-2"></a>

#### Summary: eligible population and market size

- United States population: a database analysis identified 294 individuals with an NPC diagnosis among 308 million unique individuals, an identified prevalence of 0.95 per million, and estimated 943 prevalent cases of NPC, or 2.9 cases per million people in the United States. Beren Therapeutics states that approximately half of those living with NPC in the U.S., or 475 children, have infantile-onset NPC, and that approximately two-thirds of people with NPC in the U.S. remain undiagnosed.
- Developer estimates for comparators: the developer of arimoclomol estimates approximately 2,000 individuals with NPC in the United States and Europe combined, approximately 900 of them in the United States, of whom approximately 300 to 350 have been diagnosed, and states that nearly half of the people treated with Miplyffa are adults. In manufacturer filings with California at launch, the estimated number of patients was 300 for Miplyffa and 200 for Aqneursa. Over the year from 4/1/24 to 3/31/25, 8 Oregon Health Plan members had a diagnosis indicating NPC in their medical claims.
- Market size: the developer of remibetadex expects the global market to reach more than $920 million by 2033 and presents an illustrative revenue matrix of per-patient annual price by patients treated as a percentage of approximately 943 prevalent cases, which it labels as illustrative and not a forecast.
- Priority review vouchers: on April 1, 2025, the developer of arimoclomol completed the sale of the rare pediatric disease priority review voucher it received with an approval, for net proceeds of $148.3 million, and the developer of remibetadex states that the four most recent vouchers sold for an average of approximately $200 million and that the program was extended to September 2029.

Source: [Burton et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34304992/); [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/); [Beren Therapeutics test for NPC press release (2026)](https://www.berentx.com/news/beren-therapeutics-launches-test-for-npc-to-help-identify-people-with-niemann-pick-disease-type-c-who-remain-undiagnosed/); [Zevra Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000011/zvra-20251231.htm); [California Department of Health Care Access and Information Prescription Drugs Introduced to Market, MIPLYFFA (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22Date%20Introduced%20to%20Market%22%2C%22WAC%20at%20Introduction%22%2C%22Estimated%20Number%20of%20Patients%22%20FROM%20%220e3afcfc-a5eb-41c6-a633-deaa2bfb5710%22%20WHERE%20%22Drug%20Product%20Description%22%20LIKE%20%27Miplyffa%25%27); [California Department of Health Care Access and Information Prescription Drugs Introduced to Market (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22Date%20Introduced%20to%20Market%22%2C%22WAC%20at%20Introduction%22%2C%22Estimated%20Number%20of%20Patients%22%2C%22Breakthrough%20Therapy%20Indicator%22%2C%22Priority%20Review%20Indicator%22%2C%22General%20Comments%22%20FROM%20%220e3afcfc-a5eb-41c6-a633-deaa2bfb5710%22%20WHERE%20%22NDC%20Number%22%20%3D%20%2783853010101%27); [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf); [Rafael Holdings investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026117552/ea031154001ex99-1.htm); [Rafael Holdings Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026113659/ea0309115-10k_rafael.htm)

<a id="topic-4.1-3"></a>

#### Summary: health technology assessments and published economic analyses

- Adrabetadex: the NICE appraisal of VTS-270 for Niemann-Pick type C1 was suspended after information the company provided in July 2023 and then discontinued, and the company advised that it is no longer pursuing a Marketing Authorisation Application from the MHRA for this indication.
- Comparators outside the United States: the NICE appraisal of arimoclomol was suspended after a statement by Orphazyme on 23 February 2022. The Scottish Medicines Consortium does not recommend miglustat for Niemann-Pick type C disease because the marketing authorisation holder made no submission. Ontario's Ministry considers requests for reimbursement of Zavesca (miglustat) for NPC under stated criteria.
- Oregon Medicaid: the Oregon State University Drug Use Research and Management Program reviewed Miplyffa and Aqneursa in December 2025 and found low-certainty evidence from one phase III crossover trial (n=60) that levacetylleucine improves ataxia symptoms over 12 weeks and no comparative data between arimoclomol with miglustat and levacetylleucine. It recommended making arimoclomol and levacetylleucine non-preferred with prior authorization, and miglustat (Zavesca) brand was made preferred after evaluation of costs. Both agents are on a list proposed, beginning in January 2026, to be carved out of Coordinated Care Organization payments as medications with an estimated acquisition cost of more than $500,000 per member over a 12-month period.
- Published economic analyses: one cost-effectiveness analysis in NPC is quoted, a discrete-event simulation of miglustat against symptomatic therapy from the perspective of the Serbian Republic Health Insurance Fund over a time horizon of eighty years, which found miglustat “not cost-effective when compared with symptomatic therapy” with negative values of net monetary benefit regardless of the onset of neurological manifestations. No published economic evaluation of adrabetadex is quoted.

Source: [NICE VTS-270 appraisal (2026)](https://www.nice.org.uk/guidance/discontinued/gid-hst10020); [NICE arimoclomol appraisal (2022)](https://www.nice.org.uk/guidance/indevelopment/gid-hst10037); [Scottish Medicines Consortium (2010)](https://scottishmedicines.org.uk/medicines-advice/miglustat-zavesca-nonsubmission-63210/); [Ontario Exceptional Access Program Zavesca reimbursement guidelines (2011)](https://files.ontario.ca/moh-reimbursement-guidelines-zavesca.pdf); [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf); [Gutić et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36243834/)

<a id="topic-4.1-4"></a>

#### Annual list and net prices at launch of arimoclomol and levacetylleucine: ICER launch price report

> “The annual net price at launch was $576,661 for Aqneursa and $940,586 for Miplyffa.”
> “ICER has not previously reviewed the clinical effectiveness and cost-effectiveness of Aqneursa and Miplyffa.”

Source: [ICER Launch Price and Access Report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_2026_Launch-Price-and-Access-Final-Report_ForPublication-1.pdf)

| Drug | Annual list price | Best annual net price estimate | Dosing assumption |
| --- | --- | --- | --- |
| Miplyffa (arimoclomol) | “$967,432.50” | “$940,586.25” | “We used the dosing regimen for patients weighing 30 kg to 55 kg.” |
| Aqneursa (levacetylleucine) | “$701,321.42” | “$576,661.54” | “We used the dosing regimen for patients weighing 35 kg or more.” |

Source: [ICER Launch Price and Access Report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_2026_Launch-Price-and-Access-Final-Report_ForPublication-1.pdf)

> “We converted unit WAC prices to annual WAC prices using the dosage information available on the FDA label.”

Source: [ICER Launch Price and Access Report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_2026_Launch-Price-and-Access-Final-Report_ForPublication-1.pdf)

<a id="topic-4.1-5"></a>

#### Arimoclomol: wholesale acquisition cost at U.S. introduction, manufacturer filing with the California Department of Health Care Access and Information

| Drug product description | National drug code | Date introduced to market | Wholesale acquisition cost at introduction (USD) | Estimated number of patients |
| --- | --- | --- | --- | --- |
| “Miplyffa / 47 mg” | “72542014701” | “2024-09-23” | “40185.0000” | “300” |
| “Miplyffa / 62 mg” | “72542016201” | “2024-09-23” | “53010.0000” | “300” |
| “Miplyffa / 93 mg” | “72542019301” | “2024-09-23” | “79515.0000” | “300” |
| “Miplyffa / 124 mg” | “72542012401” | “2024-09-23” | “106020.0000” | “300” |

Source: [California Department of Health Care Access and Information Prescription Drugs Introduced to Market, MIPLYFFA (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22Date%20Introduced%20to%20Market%22%2C%22WAC%20at%20Introduction%22%2C%22Estimated%20Number%20of%20Patients%22%20FROM%20%220e3afcfc-a5eb-41c6-a633-deaa2bfb5710%22%20WHERE%20%22Drug%20Product%20Description%22%20LIKE%20%27Miplyffa%25%27)

<a id="topic-4.1-6"></a>

#### Arimoclomol: wholesale acquisition cost on 1 January 2026, manufacturer report to the Texas Department of State Health Services

| Manufacturer name | Drug trade name | National drug code | Wholesale acquisition cost on 1 January 2026 (USD) |
| --- | --- | --- | --- |
| “Acer Therapeutics, Inc” | “MIPLYFFA” | “72542014701” | “40185” |
| “Acer Therapeutics, Inc” | “MIPLYFFA” | “72542016201” | “53010” |
| “Acer Therapeutics, Inc” | “MIPLYFFA” | “72542019301” | “79515” |
| “Acer Therapeutics, Inc” | “MIPLYFFA” | “72542012401” | “106020” |

Source: [Texas Department of State Health Services 2026 Annual WAC Report (2026)](https://www.dshs.texas.gov/sites/default/files/CP-TexasRX/files/2026-annual-wac-report_1026.xlsx)

<a id="topic-4.1-7"></a>

#### Arimoclomol: wholesale acquisition cost on 1 January 2025, manufacturer report to the Texas Department of State Health Services

| Drug trade name | National drug code | Wholesale acquisition cost on 1 January 2025 (USD) | Comments |
| --- | --- | --- | --- |
| “MIPLYFFA” | “72542016201” | “53010” | “Note that Acer Therapeutics is a subsidiary of Zevra Therapeutics” |
| “MIPLYFFA” | “72542019301” | “79515” | “Note that Acer Therapeutics is a subsidiary of Zevra Therapeutics” |
| “MIPLYFFA” | “72542012401” | “106020” | “Note that Acer Therapeutics is a subsidiary of Zevra Therapeutics” |

Source: [Texas Department of State Health Services 2025 Annual WAC Report (2026)](https://www.dshs.texas.gov/sites/default/files/CP-TexasRX/files/2025-annual-wac-report_0226.xlsx)

<a id="topic-4.1-8"></a>

#### Arimoclomol: Federal Supply Schedule prices per bottle of 90 capsules

| Quoted trade name | Quoted package | Quoted price (USD) | Quoted price start date | Quoted price type |
| --- | --- | --- | --- | --- |
| “MIPLYFFA 47MG CAP,ORAL” | “90” | “30080.19” | “01/01/2026” | “FSS” |
| “MIPLYFFA 62MG CAP,ORAL” | “90” | “39680.25” | “01/01/2026” | “FSS” |
| “MIPLYFFA 93MG CAP,ORAL” | “90” | “59520.37” | “01/01/2026” | “FSS” |
| “MIPLYFFA 124MG CAP,ORAL” | “90” | “79360.50” | “01/01/2026” | “FSS” |

Source: [Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026)](https://www.va.gov/opal/docs/nac/fss/vaFssPharmPrices.xlsx)

<a id="topic-4.1-9"></a>

#### Miglustat 100 mg capsules: Federal Supply Schedule and Big Four prices

| Quoted vendor | Quoted trade name | Quoted package | Quoted price (USD) | Quoted price type |
| --- | --- | --- | --- | --- |
| “Actelion Pharmaceuticals, U.S. Inc.” | “ZAVESCA 100MG CAP” | “90” | “16811.69” | “FSS” |
| “Actelion Pharmaceuticals, U.S. Inc.” | “ZAVESCA 100MG CAP” | “90” | “12589.91” | “Big4” |
| “Health Care Systems, Inc. obo Patriot Pharm” | “MIGLUSTAT 100MG CAP” | “6X15” | “4644.83” | “FSS” |

Source: [Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026)](https://www.va.gov/opal/docs/nac/fss/vaFssPharmPrices.xlsx)

<a id="topic-4.1-10"></a>

#### Levacetylleucine: wholesale acquisition cost at U.S. introduction, manufacturer filing with the California Department of Health Care Access and Information

| Field | Quoted record |
| --- | --- |
| Manufacturer name | “Intrabio Inc.” |
| National drug code | “83853010101” |
| Drug product description | “Aqneursa (levacetylleucine) 1 gram sachet, carton of 28” |
| Date introduced to market | “2024-09-24” |
| Wholesale acquisition cost at introduction (USD) | “13450.0000” |

Source: [California Department of Health Care Access and Information Prescription Drugs Introduced to Market (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22Date%20Introduced%20to%20Market%22%2C%22WAC%20at%20Introduction%22%2C%22Estimated%20Number%20of%20Patients%22%2C%22Breakthrough%20Therapy%20Indicator%22%2C%22Priority%20Review%20Indicator%22%2C%22General%20Comments%22%20FROM%20%220e3afcfc-a5eb-41c6-a633-deaa2bfb5710%22%20WHERE%20%22NDC%20Number%22%20%3D%20%2783853010101%27)

<a id="topic-4.1-11"></a>

#### Levacetylleucine: wholesale acquisition cost on 1 January 2026, manufacturer report to the Texas Department of State Health Services

| Field | Quoted record |
| --- | --- |
| Manufacturer name | “Intrabio, Inc.” |
| Drug trade name | “Aqneursa” |
| Drug generic name | “Levacetylleucine” |
| Wholesale acquisition cost on 1 January 2026 (USD) | “14526” |

Source: [Texas Department of State Health Services 2026 Annual WAC Report (2026)](https://www.dshs.texas.gov/sites/default/files/CP-TexasRX/files/2026-annual-wac-report_1026.xlsx)

> “Manufacturers report their Jan. 1 Wholesale Acquisition Cost (WAC) price annually.”
> “This table provides a list of Jan. 1, 2026 WAC pricing on all United States Food and Drug Administration-approved prescription drugs sold in or into Texas from pharmaceutical manufacturers that provided information.”

Source: [Texas Department of State Health Services Prescription Drug Price Disclosure Program data overview](https://www.dshs.texas.gov/prescription-drug-price-disclosure-program/data-overview)

<a id="topic-4.1-12"></a>

#### Levacetylleucine: wholesale acquisition cost on 1 January 2025, manufacturer report to the Texas Department of State Health Services

| Field | Quoted record |
| --- | --- |
| Manufacturer name | “IntraBio Inc.” |
| Drug trade name | “Aqneursa” |
| National drug code | “83853010101” |
| Wholesale acquisition cost on 1 January 2025 (USD) | “13450” |

Source: [Texas Department of State Health Services 2025 Annual WAC Report (2026)](https://www.dshs.texas.gov/sites/default/files/CP-TexasRX/files/2025-annual-wac-report_0226.xlsx)

<a id="topic-4.1-13"></a>

#### Levacetylleucine: cost per packet and cost at the maximum labeled dose, Oklahoma Medicaid review, February 2025

| Product | Cost per unit | Cost per 30 days | Cost per year |
| --- | --- | --- | --- |
| Aqneursa (levacetylleucine) 1 g packet | “$480.36” | “$57,643.20” | “$691,718.40” |

Source: [Oklahoma Health Care Authority Drug Utilization Review Board packet (2025)](https://oklahoma.gov/content/dam/ok/en/okhca/docs/about/boards-and-committees/dur/2025/march/03122025%20DUR%20Packet.pdf)

> “Cost per 30 days based on the FDA approved max dose of 4g per day.”
> “Unit = each capsule or packet”
> “Costs do not reflect rebated prices or net costs. Costs based on National Average Drug Acquisition Costs (NADAC), Wholesale Acquisition Costs (WAC), or State Maximum Allowable Costs (SMAC).”

Source: [Oklahoma Health Care Authority Drug Utilization Review Board packet (2025)](https://oklahoma.gov/content/dam/ok/en/okhca/docs/about/boards-and-committees/dur/2025/march/03122025%20DUR%20Packet.pdf)

<a id="topic-4.1-14"></a>

#### Levacetylleucine: Federal Supply Schedule and Big Four prices per carton of 28 packets

| Price type | Quoted trade name | Quoted package | Quoted price (USD) | Quoted price start date | Quoted price stop date |
| --- | --- | --- | --- | --- | --- |
| Federal Supply Schedule | “AQNEURSA 1GM/PKT GRANULES” | “28” | “13339.54” | “01/01/2026” | “06/30/2030” |
| Big Four | “AQNEURSA 1GM/PKT GRANULES” | “28” | “10206.02” | “01/01/2026” | “06/30/2030” |

Source: [Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026)](https://www.va.gov/opal/docs/nac/fss/vaFssPharmPrices.xlsx)

<a id="topic-4.1-15"></a>

#### Levacetylleucine: New York Medicaid maximum reimbursable amount per packet, list effective 29 September 2026

| Field | Quoted record |
| --- | --- |
| Description | “AQNEURSA 1 GRAM GRANULE PACKET” |
| National drug code | “83853-0101-01” |
| Maximum reimbursable amount cost | “555.7142800” |
| Basis of maximum reimbursable amount | “EA” |
| Effective date | “09/29/2026” |
| Maximum quantity | “112.000” |

Source: [New York State Medicaid list of reimbursable drugs (2026)](https://docs.emedny.org/ReimbursableDrugs/MedReimbDrugsFormulary.csv)

> “Displays the maximum total reimbursement per drug unit.”

Source: [New York State Medicaid eMedNY](https://www.emedny.org/info/formfile.aspx)

<a id="topic-4.1-16"></a>

#### Levacetylleucine: manufacturer estimate of the U.S. population at the 2024 launch, California filing

| Field | Quoted record |
| --- | --- |
| Estimated number of patients | “200” |
| General comments | “This is a new and novel therapy for a disease called NPC Neimann Pick C. There were no previously approved indicated therapies for NPC.” |

Source: [California Department of Health Care Access and Information Prescription Drugs Introduced to Market (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22Date%20Introduced%20to%20Market%22%2C%22WAC%20at%20Introduction%22%2C%22Estimated%20Number%20of%20Patients%22%2C%22Breakthrough%20Therapy%20Indicator%22%2C%22Priority%20Review%20Indicator%22%2C%22General%20Comments%22%20FROM%20%220e3afcfc-a5eb-41c6-a633-deaa2bfb5710%22%20WHERE%20%22NDC%20Number%22%20%3D%20%2783853010101%27)

<a id="topic-4.1-17"></a>

#### Arimoclomol: Medicaid utilization and reimbursement, national totals, fourth quarter 2025

| Strength and delivery system | Quoted national drug code | Quoted units reimbursed | Quoted number of prescriptions | Quoted total amount reimbursed (USD) |
| --- | --- | --- | --- | --- |
| 124 mg, fee-for-service | “72542012401” | “1440.000” | “16” | “1696457.51” |
| 124 mg, managed care | “72542012401” | “1710.000” | “19” | “2009670.07” |
| 93 mg, fee-for-service | “72542019301” | “1170.000” | “13” | “1033077.71” |
| 93 mg, managed care | “72542019301” | “1710.000” | “19” | “1552152.01” |
| 62 mg, fee-for-service | “72542016201” | “1530.000” | “17” | “900554.24” |
| 62 mg, managed care | “72542016201” | “1622.000” | “20” | “1078098.37” |

Source: [Medicaid.gov State Drug Utilization Data 2025 for MIPLYFFA (2026)](https://data.medicaid.gov/api/1/datastore/query/158a1baa-5506-400a-8ec3-97756f0b0536/0?conditions%5B0%5D%5Bproperty%5D=product_name&conditions%5B0%5D%5Bvalue%5D=MIPLYFFA%25&conditions%5B0%5D%5Boperator%5D=like&conditions%5B1%5D%5Bproperty%5D=state&conditions%5B1%5D%5Bvalue%5D=XX&conditions%5B1%5D%5Boperator%5D=%3D&limit=50&properties%5B%5D=utilization_type&properties%5B%5D=ndc&properties%5B%5D=product_name&properties%5B%5D=year&properties%5B%5D=quarter&properties%5B%5D=suppression_used&properties%5B%5D=units_reimbursed&properties%5B%5D=number_of_prescriptions&properties%5B%5D=total_amount_reimbursed&sorts%5B0%5D%5Bproperty%5D=ndc&sorts%5B0%5D%5Border%5D=asc&sorts%5B1%5D%5Bproperty%5D=quarter&sorts%5B1%5D%5Border%5D=asc&schema=false&keys=true&count=false)

<a id="topic-4.1-18"></a>

#### Arimoclomol: Medicaid utilization and reimbursement, national totals, first quarter 2026

| Strength and delivery system | Quoted national drug code | Quoted units reimbursed | Quoted number of prescriptions | Quoted total amount reimbursed (USD) |
| --- | --- | --- | --- | --- |
| 124 mg, fee-for-service | “72542012401” | “1710.000” | “19” | “2081853.23” |
| 124 mg, managed care | “72542012401” | “1170.000” | “13” | “1436319.97” |
| 93 mg, fee-for-service | “72542019301” | “1260.000” | “14” | “1154516.46” |
| 93 mg, managed care | “72542019301” | “1710.000” | “19” | “1792307.75” |
| 62 mg, fee-for-service | “72542016201” | “1713.000” | “22” | “1203793.11” |
| 62 mg, managed care | “72542016201” | “1080.000” | “12” | “670388.98” |

Source: [Medicaid.gov State Drug Utilization Data 2026 for MIPLYFFA (2026)](https://data.medicaid.gov/api/1/datastore/query/2957a7f9-9a15-453e-9afd-3bbdcbac8fd3/0?conditions%5B0%5D%5Bproperty%5D=product_name&conditions%5B0%5D%5Bvalue%5D=MIPLYFFA%25&conditions%5B0%5D%5Boperator%5D=like&conditions%5B1%5D%5Bproperty%5D=state&conditions%5B1%5D%5Bvalue%5D=XX&conditions%5B1%5D%5Boperator%5D=%3D&limit=50&properties%5B%5D=utilization_type&properties%5B%5D=ndc&properties%5B%5D=product_name&properties%5B%5D=year&properties%5B%5D=quarter&properties%5B%5D=suppression_used&properties%5B%5D=units_reimbursed&properties%5B%5D=number_of_prescriptions&properties%5B%5D=total_amount_reimbursed&sorts%5B0%5D%5Bproperty%5D=ndc&sorts%5B0%5D%5Border%5D=asc&sorts%5B1%5D%5Bproperty%5D=quarter&sorts%5B1%5D%5Border%5D=asc&schema=false&keys=true&count=false)

<a id="topic-4.1-19"></a>

#### Levacetylleucine: Medicaid utilization and reimbursement, national totals by quarter, 2025

| Quarter and delivery system | Quoted units reimbursed | Quoted number of prescriptions | Quoted total amount reimbursed (USD) | Quoted Medicaid amount reimbursed (USD) |
| --- | --- | --- | --- | --- |
| First quarter 2025, managed care | “2604.000” | “33” | “1264504.78” | “1264504.78” |
| Second quarter 2025, fee-for-service | “3080.000” | “36” | “1454153.49” | “1395177.93” |
| Second quarter 2025, managed care | “4872.000” | “61” | “2416559.79” | “2316942.59” |
| Third quarter 2025, fee-for-service | “6552.000” | “79” | “3288367.91” | “3196467.73” |
| Third quarter 2025, managed care | “6860.000” | “84” | “3530837.46” | “3413044.04” |
| Fourth quarter 2025, fee-for-service | “5852.000” | “69” | “3020119.38” | “2922717.47” |
| Fourth quarter 2025, managed care | “8400.000” | “101” | “4381592.98” | “4193836.02” |

Source: [Medicaid.gov State Drug Utilization Data 2025 (2026)](https://data.medicaid.gov/api/1/datastore/query/158a1baa-5506-400a-8ec3-97756f0b0536/0?conditions%5B0%5D%5Bproperty%5D=ndc&conditions%5B0%5D%5Bvalue%5D=83853010101&conditions%5B0%5D%5Boperator%5D=%3D&conditions%5B1%5D%5Bproperty%5D=state&conditions%5B1%5D%5Bvalue%5D=XX&conditions%5B1%5D%5Boperator%5D=%3D&limit=20&properties%5B%5D=utilization_type&properties%5B%5D=state&properties%5B%5D=ndc&properties%5B%5D=year&properties%5B%5D=quarter&properties%5B%5D=suppression_used&properties%5B%5D=product_name&properties%5B%5D=units_reimbursed&properties%5B%5D=number_of_prescriptions&properties%5B%5D=total_amount_reimbursed&properties%5B%5D=medicaid_amount_reimbursed&properties%5B%5D=non_medicaid_amount_reimbursed&sorts%5B0%5D%5Bproperty%5D=quarter&sorts%5B0%5D%5Border%5D=asc&schema=false&keys=true&count=false)

<a id="topic-4.1-20"></a>

#### Levacetylleucine: Medicaid utilization and reimbursement, national totals, first quarter 2026

| Quarter and delivery system | Quoted units reimbursed | Quoted number of prescriptions | Quoted total amount reimbursed (USD) | Quoted Medicaid amount reimbursed (USD) |
| --- | --- | --- | --- | --- |
| First quarter 2026, fee-for-service | “7728.000” | “93” | “4017756.66” | “4017744.66” |
| First quarter 2026, managed care | “6076.000” | “70” | “3160527.34” | “2874948.28” |

Source: [Medicaid.gov State Drug Utilization Data 2026 (2026)](https://data.medicaid.gov/api/1/datastore/query/2957a7f9-9a15-453e-9afd-3bbdcbac8fd3/0?conditions%5B0%5D%5Bproperty%5D=ndc&conditions%5B0%5D%5Bvalue%5D=83853010101&conditions%5B0%5D%5Boperator%5D=%3D&conditions%5B1%5D%5Bproperty%5D=state&conditions%5B1%5D%5Bvalue%5D=XX&conditions%5B1%5D%5Boperator%5D=%3D&limit=20&properties%5B%5D=utilization_type&properties%5B%5D=state&properties%5B%5D=ndc&properties%5B%5D=year&properties%5B%5D=quarter&properties%5B%5D=suppression_used&properties%5B%5D=product_name&properties%5B%5D=units_reimbursed&properties%5B%5D=number_of_prescriptions&properties%5B%5D=total_amount_reimbursed&properties%5B%5D=medicaid_amount_reimbursed&properties%5B%5D=non_medicaid_amount_reimbursed&sorts%5B0%5D%5Bproperty%5D=quarter&sorts%5B0%5D%5Border%5D=asc&schema=false&keys=true&count=false)

<a id="topic-4.1-21"></a>

#### Arimoclomol: net revenue and prescription enrollment forms, third quarter 2026

> “$37.8 million net revenue for Q3 2026, driven by $34.0 million in revenue from MIPLYFFA”
> “U.S.: Received 13 MIPLYFFA prescription enrollment forms for Niemann-Pick disease type C (NPC) during Q3 2026, bringing the total to 197 since product launch.”
> “As of September 30, 2026, 134 patients were enrolled in the global EAP.”

Source: [Zevra Therapeutics third quarter 2026 results release (2026)](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000085/zvra-20261103xex991earnings.htm)

<a id="topic-4.1-22"></a>

#### Eligible population and market size stated by the developer of arimoclomol

> “We estimate that there are approximately 2,000 individuals with NPC in the United States and Europe combined, of which approximately 900 are in the United States and 1,100 are in Europe, where there is a mature market with an approved treatment available for NPC.”
> “Of this estimated population, approximately 300 to 350 people have been diagnosed in the United States.”
> “Although it has traditionally been considered a pediatric disease due to its genetic origins, nearly half of the people treated with MIPLYFFA are adults.”

Source: [Zevra Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000011/zvra-20251231.htm)

<a id="topic-4.1-23"></a>

#### Arimoclomol prescription enrollments, December 2025, superseded in November 2026

> “As of December 31, 2025, there were a total of 161 enrollments to receive MIPLYFFA.”
> “For MIPLYFFA, an enrollment is a prescription submitted to our specialty pharmacy, initiating the benefits investigation process to determine reimbursement and can lead to a 30-day paid dispense of MIPLYFFA.”

Source: [Zevra Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000011/zvra-20251231.htm)

<a id="topic-4.1-24"></a>

#### Levacetylleucine and arimoclomol: company sales disclosure and analyst forecast, January 2026, enrollment count superseded in November 2026

> “IntraBio, a private company, has not disclosed sales figures for Aqneursa, but Zevra has secured 137 prescription enrollment forms since its NPC launch as of the third quarter.”
> “Analysts at Delveinsight expect Aqneursa to generate $500 million in peak U.S. sales in NPC.”

Source: [Fierce Pharma phase 3 results report (2026)](https://www.fiercepharma.com/pharma/intrabios-aqneursa-roll-eu-approval-races-toward-another-rare-disease-indication-phase-3-win)

<a id="topic-4.1-25"></a>

#### Value of rare pediatric disease priority review vouchers in NPC and recent sales

> “In addition, we received a transferable rare pediatric disease PRV in conjunction with the approval. On April 1, 2025, we completed the sale of the PRV and received net proceeds of $148.3 million.”

Source: [Zevra Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000011/zvra-20251231.htm)

> “Rare Pediatric Disease PRV program extended to September 2029; the four most recent vouchers sold for an average of ~$200M”

Source: [Rafael Holdings investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026117552/ea031154001ex99-1.htm)

<a id="topic-4.1-26"></a>

#### Market size and illustrative revenue presented by the developer of remibetadex

> “global market expected to reach >$920m by 2033”
> “Ultra - rare disease with established premium orphan pricing and an emerging combination paradigm”
> “Many patients may go undiagnosed or untreated given disease rarity”
> “Per - patient annual price (columns) × patients treated (rows; % of ~943 prevalent cases)”
> “Illustrative only; not a forecast .”

Source: [Rafael Holdings investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026117552/ea031154001ex99-1.htm)

<a id="topic-4.1-27"></a>

#### Health technology assessment of adrabetadex (VTS-270) in England: NICE appraisal discontinued

> “Suggested Remit: To evaluate the benefits and costs of VTS-270 within its marketing authorisation for treating Niemann-Pick type C1 for national commissioning by NHS England.”
> “Please note that following on from information provided to NICE by the company in July 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.”
> “For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time.”

Source: [NICE VTS-270 appraisal (2026)](https://www.nice.org.uk/guidance/discontinued/gid-hst10020)

<a id="topic-4.1-28"></a>

#### Health technology assessment of arimoclomol in England: NICE appraisal suspended

> “Suggested remit: To evaluate the benefits and costs of arimoclomol within its marketing authorisation for treating Niemann-Pick disease type C for national commissioning by NHS England.”
> “On 23 February 2022, the company (Orphazyme) issued a statement that it is currently assessing its strategic options following feedback on arimoclomol from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). Therefore, this evaluation will be suspended.”

Source: [NICE arimoclomol appraisal (2022)](https://www.nice.org.uk/guidance/indevelopment/gid-hst10037)

<a id="topic-4.1-29"></a>

#### Health technology assessment of miglustat in Scotland: not recommended in the absence of a submission

> “miglustat (Zavesca ®) is not recommended for use within NHSScotland for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.”
> “The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.”

Source: [Scottish Medicines Consortium (2010)](https://scottishmedicines.org.uk/medicines-advice/miglustat-zavesca-nonsubmission-63210/)

<a id="topic-4.1-30"></a>

#### Public reimbursement of miglustat for NPC in Ontario: Exceptional Access Program

> “The Ministry will consider requests for reimbursement of Zavesca (miglustat) for the treatment of Niemann Pick Type C (NPC).”
> “Initial funding for Zavesca (miglustat) under the ODB program may be considered where the patient meets the following criteria:”

Source: [Ontario Exceptional Access Program Zavesca reimbursement guidelines (2011)](https://files.ontario.ca/moh-reimbursement-guidelines-zavesca.pdf)

<a id="topic-4.1-31"></a>

#### Oregon Medicaid new drug evaluation in Niemann-Pick disease type C: scope

> “New Drug Evaluations: Miplyffa™ (arimoclomol) capsules, Aqneursa™ (levacetylleucine) oral suspension”
> “Date of Review: December 2025”
> “Dossier Received: MIPLYFFA (yes); AQNEURSA (no)”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

<a id="topic-4.1-32"></a>

#### Oregon Medicaid new drug evaluation in Niemann-Pick disease type C: evidence conclusions

> “There is low-certainty evidence from one randomized, double-blind, phase III, crossover trial that levacetylleucine improves ataxia symptoms over 12 weeks in patients 4 years of age and older with NPC (n=60) weighing at least 15 kg.”
> “There is no comparative data between treatments of arimoclomol with miglustat versus levacetylleucine.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

<a id="topic-4.1-33"></a>

#### Oregon Medicaid new drug evaluation in Niemann-Pick disease type C: recommendations

> “Make arimoclomol and levacetylleucine non-preferred on the Oregon Health Plan (OHP) Preferred Drug list (PDL).”
> “Implement prior authorization (PA) for high cost treatments for Niemann-Pick disease type C.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

<a id="topic-4.1-34"></a>

#### Oregon Medicaid new drug evaluation in Niemann-Pick disease type C: miglustat preferred status after cost review

> “Implement separate miglustat PA for 100 mg formulation with corresponding updates to PA criteria for Pompe Disease and Gaucher disease.”
> “After evaluation of costs in executive session, miglustat (Zavesca®) brand was made preferred.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

<a id="topic-4.1-35"></a>

#### Oregon Medicaid new drug evaluation in Niemann-Pick disease type C: high-cost carve-out and affected members

> “Beginning in January 2026, the Oregon Health Authority is proposing that high cost medications for rare conditions be carved out of Coordinated Care Organization (CCO) payments and billed directly to fee-for-service (FFS).”
> “Estimated acquisition cost of more than $500,000 per member over a 12-month period”
> “Both arimoclomol and levacetylleucine are currently included in the list of medications proposed to be carved-out of CCO budgets.”
> “Over a 1 year period from 4/1/24 to 3/31/25, there were 8 Oregon Health Plan members with a diagnosis indicating NPC in their medical claims.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

<a id="topic-4.1-36"></a>

#### Oregon Medicaid proposed prior authorization criteria for NPC medications

> “Ensure medically appropriate use of medications for Niemann-Pick disease Type C”
> “Is the request for arimoclomol or levacetylleucine in a patient already taking the other agent (i.e., combination therapy without documentation of planned therapeutic switch)?”
> “Has the diagnosis of Niemann-Pick disease type C been confirmed by genetic testing or a filipin test?”
> “Is the request being made by or in consultation with an expert in metabolic or genetic disease or experienced in treating Niemann-Pick disease type C?”
> “Has baseline severity been documented using NPCCSS, SARA, or some other appropriate tool for assessing Niemann-Pick disease type C?”
> “Is patient taking concomitant miglustat or starting miglustat therapy with arimoclomol initiation?”
> “Is the request for levacetylleucine in a patient weighing at least 15 kg?”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

<a id="topic-4.1-37"></a>

#### Published cost-effectiveness analysis of miglustat versus symptomatic therapy: Serbian payer perspective

> “The perspective of the Serbian Republic Health Insurance Fund was chosen for this study, and the time horizon was eighty years.”
> “The main outcomes of the study were quality-adjusted life years gained with miglustat and comparator, and direct costs of treatment.”
> “The study was conducted through the generation and simulation of the Discrete-Event Simulation model.”
> “Treatment with miglustat was not cost-effective when compared with symptomatic therapy and was associated with negative values of net monetary benefit regardless of the onset of neurological manifestations”
> “When traditional pharmacoeconomic evaluation is employed, miglustat is not a cost-effective option in comparison to symptomatic therapy for the treatment of NP-C.”

Source: [Gutić et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36243834/)

<a id="heading-4.2"></a>

### 4.2 Budget Impact Model

<a id="heading-4.2.1"></a>

#### 4.2.1 Approach and Framework

No evidence found.

<a id="heading-4.2.2"></a>

#### 4.2.2 Perspective and Time Frame

No evidence found.

<a id="heading-4.2.3"></a>

#### 4.2.3 Epidemiology and Eligible Population Inputs

No evidence found.

<a id="heading-4.2.4"></a>

#### 4.2.4 Cost Assumptions

No evidence found.

<a id="heading-4.2.5"></a>

#### 4.2.5 Model Outcomes

No evidence found.

<a id="heading-4.2.6"></a>

#### 4.2.6 Results

<a id="heading-4.2.6.1"></a>

##### 4.2.6.1 Base Case

No evidence found.

<a id="heading-4.2.6.2"></a>

##### 4.2.6.2 Scenario Analyses

No evidence found.

<a id="heading-4.2.7"></a>

#### 4.2.7 Budget impact model discussion

No evidence found.

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
